In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK)

Georgina Meneses-Lorente1 · Stephen Fowler2 · Elena Guerini2 · Karey Kowalski3 · Edna Chow-Maneval3 · Li Yu4 · Francois Mercier2 · Mohammed Ullah2 · Kenichi Umehara2 · Andreas Brink2 · Vincent Buchheit2 · Elke Zwanziger2 · Alex Phipps1 · Nassim Djebli2

Received: 15 April 2021 / Accepted: 26 July 2021 / Published online: 21 August 2021
© The Author(s) 2021

Abstract
Background Entrectinib is a CNS-active, potent inhibitor of tyrosine receptor kinases A/B/C, ROS1 and anaplastic lymphoma kinase approved for use in patients with solid tumors. We describe the in vitro and clinical studies investigating potential entrectinib drug-drug interactions.

Methods In vitro studies with human biomaterials assessed the enzymes involved in entrectinib metabolism, and whether entrectinib modulates the activity of the major cytochrome P450 (CYP) enzymes or drug transporter P-glycoprotein. Clinical studies investigated the effect of a strong CYP3A4 inhibitor (itraconazole) and inducer (rifampin) on single-dose entrectinib pharmacokinetics. The effect of entrectinib on sensitive probe substrates for CYP3A4 (midazolam) and P-glycoprotein (digoxin) were also investigated.

Results Entrectinib is primarily metabolized by CYP3A4. In vitro, entrectinib is a CYP3A4/5 inhibitor (IC50 2 μM) and a weak CYP3A4 inducer. Entrectinib inhibited P-glycoprotein (IC50 1.33 μM) but is a poor substrate. In healthy subjects, itraconazole increased entrectinib Cmax and AUC by 73% and 504%, respectively, and rifampin decreased entrectinib Cmax and AUC by 56% and 77%, respectively. Single dose entrectinib did not affect midazolam AUC, although Cmax decreased by 34%. Multiple dose entrectinib increased midazolam AUC by 50% and decreased Cmax by 21%. Single dose entrectinib increased digoxin AUC and Cmax by 18% and 28%, respectively, but did not affect digoxin renal clearance.

Conclusions Entrectinib is a CYP3A4 substrate and is sensitive to the effects of coadministered moderate/strong CYP3A4 inhibitors and strong inducers, and requires dose adjustment. Entrectinib is a weak inhibitor of CYP3A4 and P-glycoprotein and no dose adjustments are required with CYP3A4/P-glycoprotein substrates.

Registration Number (Study 2) NCT03330990 (first posted online November 6, 2017) As studies 1 and 3 are phase 1 trials in healthy subjects, they are not required to be registered.

Keywords Entrectinib · TRK/ROS1/ALK · Drug-drug interactions · CYP3A4 · P-glycoprotein

Introduction
Entrectinib (also known as RXDX-101 and Rozlytrek®) is a CNS-active, potent and selective inhibitor of tyrosine receptor kinases (TRK) A/B/C, ROS1 and anaplastic lymphoma kinase (ALK), which are encoded by the genes neurotrophic tyrosine receptor kinase (NTRK) 1/2/3, ROS1, and ALK, respectively. These kinases are overexpressed or dysregulated in cancer with constitutive activity, making the growth of the cancer cells dependent on the abnormal kinases [1, 2]. Molecular alterations in kinases are found in many types of cancer and therefore represent attractive targets for anticancer therapy [3]. Entrectinib has been shown to have antitumor activity in advanced and/or metastatic solid tumors [4–6], and has recently been approved in the several regions (including the US, EU, Japan and Canada) for the treatment of adult and/or pediatric patients with tumors that harbor NTRK1/2/3 or ROS1 gene rearrangements. The
recommended dosage in adults is 600 mg orally once daily with or without food.

In a mass balance study, entrectinib has been shown to be mainly eliminated through hepatic clearance, with negligible renal clearance (<1% of the dose is excreted unchanged in urine) [7]. There are two major circulating metabolites of entrectinib in humans, M5 and M11, contributing 12% and 19%, respectively, of total circulating radioactivity. M5 is a product of N-demethylation and M11 is formed by N-glucuronidation. M5 is pharmacologically active and therefore its pharmacokinetics have been assessed during entrectinib development. M11 is not pharmacologically active and as a glucuronide was not considered MIST-relevant [8].

As entrectinib is used to treat cancer patients, it is expected to be coadministered with many other drugs including known drug metabolizing enzyme inhibitors such as antivirals (eg, ritonavir), macrolide antibiotics (eg, telithromycin), antifungals (eg, itraconazole) and inducers such as rifampin, carbamazepine and phenytoin. It is therefore important to understand the potential for drug-drug interactions (DDIs) both with respect to entrectinib as a victim and as a perpetrator. In vitro and clinical studies were conducted to assess the DDI potential of entrectinib. In vitro studies using human hepatocytes, human liver microsomes and cDNA-expressed human cytochrome P450 (CYP) enzymes, investigated which enzymes are primarily involved in the metabolism of entrectinib and in the formation of M5. In vitro studies also assessed whether entrectinib and M5 are substrates for drug transporters. The results of these studies were used to guide targeted clinical assessment of potential DDIs with drugs known to be strong inhibitors or inducers of the relevant enzymes and/or transporters to assess the magnitude of any changes in entrectinib exposure. Further in vitro studies using human hepatocytes, human liver microsomes, human P-glycoprotein (P-gp) expressing cell lines, and Caco-2 and MDCKII-MDR1 cells, were designed to investigate the potential of entrectinib and M5, to modulate the activity of CYP enzymes and P-gp. The results of these studies were used to guide further clinical studies to assess whether coadministration of entrectinib with substrates of these enzymes/transporters lead to changes in the substrate’s exposure.

Here we report a summary of the in vitro studies conducted with entrectinib and M5, and the results of 3 clinical DDI studies conducted in either cancer patients or healthy subjects. The first clinical study described here investigated the effect of a strong CYP3A4 inhibitor (itraconazole) and a strong CYP3A4 inducer (rifampin) on the pharmacokinetics of entrectinib and M5. The second clinical study assessed the effect of entrectinib on the pharmacokinetics of midazolam, a sensitive CYP3A4 substrate. The third clinical study investigated the effect of entrectinib on the pharmacokinetics of digoxin, a sensitive substrate of P-glycoprotein (P-gp). The results of these studies were used to guide dosing recommendations for entrectinib.

**Methods**

**In vitro studies**

The metabolic profile of entrectinib has been investigated in vitro in studies using [14] Centrectinib in both human liver microsomes and human hepatocytes. In addition, the metabolism of entrectinib was investigated using 12 cDNA-expressed human CYP enzymes: CYPs 1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2C18, 2C19, 2D6, 2E1, 3A4 and 3A5. The effect of CYP-selective chemical inhibitors on the metabolism of entrectinib by pooled human liver microsomes was also investigated. The selective inhibitors used were α-naphthoflavone (CYP1A2), ticlopidine (CYP2B6), montelukast (CYP2C8), sulfinpyrazone (CYP2C9), benzylphenobarbital (CYP2C19), quinidine (CYP2D6) and ketoconazole (CYP3A).

The in vitro inhibition of human CYPs 1A2, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A by entrectinib and M5 was investigated in human liver microsomes. In vitro induction of CYP mRNA (CYPs 1A2, 2C8, 2C9 and 3A4) or enzyme activity (CYPs 1A2, 2C19 and 3A4) was assessed in human hepatocytes.

The potential of entrectinib and M5 to be substrates of P-gp was assessed in studies in Caco-2 cells and MDCKII-MDR1 cells. In addition, the potential for entrectinib and M5 to inhibit P-gp was also assessed.

Outlines of the in vitro studies describing key reagents, timepoints and conditions are included in the supplementary material.

**Clinical studies**

**Clinical study design**

In all 3 studies, subjects provided written informed consent and underwent screening procedures to confirm eligibility for each study within 3 to 4 weeks prior to receiving any study medication.

Study 1 was an open-label, fixed-sequence, 2-cohort, single-center study in healthy adult subjects to evaluate the effect of a strong CYP3A4 inhibitor (itraconazole) and a strong CYP3A4 inducer (rifampin) on the pharmacokinetics of entrectinib and M5. In Cohort 1, subjects received a single dose of 100 mg entrectinib on Day 1 (Period 1). This dose was chosen as it was expected that when it was administered with a strong CYP3A4 inhibitor entrectinib exposure would not exceed the exposure seen with 600 mg entrectinib...
alone. After a 9-day washout, subjects received 200 mg once daily (QD) itraconazole on Days 10 through 19 and a single dose of 100 mg entrectinib 1 h after itraconazole on Day 14 (Period 2). Entrectinib was administered 1 h later than itraconazole in an attempt to match the peak concentrations for both compounds to maximize the potential for interactions. On Days 1 and 14, subjects were fasted for 10 h prior to, and for 4 h after entrectinib dosing. Subjects were resident in the study center from Day -1 through Day 3, and from Day 13 through Day 16. All doses of study medication were administered at the study center. Blood samples for entrectinib and M5 plasma concentrations were collected at intervals from prior to entrectinib dosing through to 144 h after entrectinib dosing on Days 1 and 14.

In Cohort 2, subjects received a single dose of 600 mg entrectinib on Day 1 (Period 1). After a 9-day washout, subjects received 600 mg QD rifampin on Days 10 through 25 (Period 2) and a single dose of 600 mg entrectinib concurrently with rifampin on Day 21. On Days 1 and 21, subjects were fasted for 10 h prior to, and for 4 h after entrectinib dosing. Subjects were resident in the study center from Day -1 through Day 3, and from Day 20 through Day 23. All doses of study medication were administered at the study center. Blood samples for entrectinib and M5 plasma concentrations were collected at intervals from prior to entrectinib dosing through to 120 h after entrectinib dosing on Days 1 and 21.

Study 2 (NCT03330990) was an open-label, fixed-sequence, 3-center study in subjects with advanced solid tumors to evaluate the effect of multiple doses of entrectinib on the single-dose pharmacokinetics of midazolam and its active metabolite 1’-hydroxymidazolam. Subjects received 2 mg midazolam (midazolam hydrochloride syrup) orally on Days 1, 8 and 21 under fasted conditions. Entrectinib (600 mg/day orally) dosing began on Day 8 and continued through Day 22. Entrectinib was self-administered on Days 10 through 20. On Days 8 and 21, midazolam was administered 1 h after entrectinib. On Days 1, 8 and 21, blood samples for midazolam and 1’-hydroxymidazolam plasma concentrations were collected from 1 h prior to midazolam dose, and at intervals up to 34 h post-midazolam dose. Following completion of this part of the study, subjects could continue in an expanded access portion of the study which is not discussed here.

Study 3 was an open-label, fixed-sequence, single-center study in healthy adult subjects to evaluate the effect of entrectinib on the pharmacokinetics of oral digoxin. Subjects received a single dose of 0.5 mg digoxin on Day 1 (Period 1) under fasted conditions. After a 10-day washout, subjects received a single oral dose of 600 mg entrectinib, 1 h prior to administration of 0.5 mg digoxin on Day 11, under fasting conditions (Period 2). Subjects were resident in the study center from Day -1 through Day 4 and from Day 10 through Day 14. Blood samples for digoxin plasma concentrations were collected at intervals from prior to digoxin dosing through to 144 h after digoxin dosing on Days 1 and 11. Urine samples for digoxin concentrations were collected from prior to digoxin dosing and up to 72 h after digoxin dosing on Days 1 and 11.

Subjects

Studies 1 and 3 included healthy adult subjects (males only in Study 3). Key exclusion criteria included restrictions of any prescription drugs for at least 14 days (or 5 half-lives) prior to Day 1, any over-the-counter medication within 7 days of Day 1 (unless agreed by the Principal Investigator and Sponsor as not clinically relevant), and any investigational drug in any clinical trial within 30 days (or 5 half-lives) prior to Day 1. Use of drugs with enzyme-inducing properties or strong CYP3A4 inhibitors within 4 weeks prior to Day 1 were also excluded.

Study 2 included adult male and female subjects who had a histologically or cytologically confirmed diagnosis of advanced or metastatic solid tumors not responsive to standard therapies or for which there was not effective therapy. Subjects were initially required, and after an amendment, subsequently preferred to have tumors harboring NTRK1/2/3, ROS1, or ALK molecular alterations. Prior cancer therapy was allowed, but had to have been completed within prespecified time-limits prior to the start of midazolam dosing. Subjects had to have an ECOG performance status score of ≤ 1, and have adequate hematologic, liver and renal function. Use of strong CYP3A inhibitors or inducers was not allowed within 14 days prior to the start of midazolam dosing.

Pharmacokinetic assessments

Entrectinib and M5 plasma concentrations were measured using a validated liquid chromatography-tandem mass spectrometry (LC–MS/MS) method with a lower limit of quantification (LLOQ) of 2.00 ng/mL for both analytes. Midazolam and 1’-hydroxymidazolam plasma concentrations were measured using a validated LC–MS/MS method with an LLOQ of 0.100 ng/mL for both analytes. Digoxin plasma and urine concentrations were measured using a validated LC–MS/MS method with an LLOQ of 0.100 ng/mL (plasma) and 0.200 ng/mL (urine), respectively.

PK parameters were determined using noncompartmental analysis (Phoenix WinNonlin software, Certara, NJ, USA). PK parameters included maximum plasma concentration (C\text{max}), time to C\text{max} (T\text{max}), area under the curve (AUC) from time zero to 24 h post dose (AUC_{0-24}), AUC extrapolated to infinity (AUC_{\text{inf}}), terminal half-life (t_1/2), where appropriate. The molar AUC_{\text{inf}} and C\text{max} ratios of 1’-hydroxymidazolam
to midazolam were also calculated in Study 2. The percent of the dose of digoxin recovered unchanged in urine (\(f_u\)) and renal clearance (\(\text{CLR}\)) were calculated from urine data in Study 3.

**Statistical assessments and sample size**

No formal calculations on sample size were made for any of the studies. Ten subjects in each cohort of Study 1, and in total in Study 3 were deemed sufficient based on similar phase 1 studies. In Study 2, up to 15 subjects were to be enrolled to provide a final dataset of at least 8 evaluable subjects which was considered typical for studies of this nature.

For all studies, a mixed effects model with fixed effect for treatment and a random subject effect were used to analyze the logarithms of AUC\(_{\text{inf}}\), and C\(_{\text{max}}\). For each treatment comparison, a point estimate and 90% confidence interval (CI) were provided for the geometric mean ratio. Lack of interaction was concluded if the 90% CI for the ratio was fully contained within 80% to 125% for each parameter.

### Results

#### In vitro metabolism of entrectinib

Moderate turnover of entrectinib was observed in human hepatocytes, with 29% of the drug metabolized after 120 min of incubation. Similarly, 47% of parent remained after 60 min of incubation with pooled human liver microsomes supplemented with NADPH. The main metabolite formed in both profiling studies was M5 (N-demethylation at the piperazine). M5 accounted for 12% of total drug-related material (representing 41% of entrectinib metabolism) in human hepatocytes, and for 28% of the [14] Centrectinib-derived radioactivity in human liver microsomes. All other metabolites together accounted for less than 20% of metabolism in hepatocytes and less than 10% of the radioactivity in microsomes. Studies using long-term micropatterned co-cultured human hepatocytes suggested that M5 exhibited an approximately twofold lower intrinsic clearance than entrectinib.

Studies with CYP-selective inhibitors on the metabolism of entrectinib demonstrated a strong effect of ketoconazole (approximately 50–80% inhibition depending on the metabolite formed), indicating an important role for CYP3A enzymes in the oxidative metabolism of entrectinib (especially demethylation to M5). Other enzymes may also contribute to some extent, but no contributions exceeding 25% were observed for any of the metabolism pathways in vitro (Table 1). The CYP reaction phenotyping studies with cDNA-expressed human CYP enzymes, also suggested that entrectinib metabolites were formed by multiple CYPs but that CYP3A4 was substantially more active than the other enzyme preparations. CYP3A4 was also shown to catalyze both the generation and further metabolism of M5 (Table S1).

**Table 1** Effect of CYP-Selective Inhibitors on the Metabolism of 1µM Entrectinib by Pooled Human Liver Microsomes

| Test Inhibitor          | Enzyme Target | % Inhibition of Entrectinib Metabolism to M5 | Effect on Formation of other Entrectinib Metabolites |
|-------------------------|---------------|--------------------------------------------|------------------------------------------------------|
| α-Naphthoflavone (0.5 µM) | CYP1A2        | < 20                                       | -                                                    |
| Ticlopidine (50 µM)      | CYP2B6        | < 20                                       | -                                                    |
| Montelukast (3 µM)       | CYP2C8        | < 20                                       | +                                                    |
| Sulfaphenazole (10 µM)   | CYP2C9        | < 20                                       | -                                                    |
| Benzylyphenobarbital (10 µM) | CYP2C19     | < 20                                       | -                                                    |
| Quinidine (1 µM)         | CYP2D6        | < 20                                       | +                                                    |
| Ketoconazole (1 µM)      | CYP3A4/5      | 82 ± 3                                     | ++                                                   |

+ + + > 50% inhibition of multiple metabolites, + + > 50% inhibition of 1 metabolite or > 20% inhibition of multiple metabolites, + > 20% inhibition of 1 metabolite, —< 20% inhibition of any metabolites

### Table 2 In vitro inhibition of human drug metabolizing enzymes and transport proteins by entrectinib and M5

| IC\(_{50}\) (µM) | Entrectinib | M5 |
|------------------|-------------|----|
| Drug Metabolizing Enzymes |            |    |    |
| CYP1A2           | > 10        | > 10|
| CYP2B6           | > 10        | > 10|
| CYP2C8           | > 10        | 4.9 |
| CYP2C9           | > 10        | > 10|
| CYP2C19          | > 10        | > 10|
| CYP2D6           | > 10        | > 10|
| CYP3A4/5         | 2.0         | > 10|
| Transport Proteins | MDR1 (P-gp) | 1.3| 10 |

CYP cytochrome P450, MDR multidrug resistance, P-gp P-glycoprotein

Entrectinib was a very weak time-dependent inhibitor (TDI) of CYP3A4 but \(K_e\) and \(k_{\text{inact}}\) could not be measured in vitro as the TDI signal was too low.
In vitro inhibition and induction of cyps by entrectinib and m5

Studies in human liver microsomes demonstrated that entrectinib inhibited CYP3A4/5 with an IC$_{50}$ of 2 μM (Table 2). The IC$_{50}$ values for entrectinib and the other CYPs tested were > 10 μM. M5 appeared to be less inhibitory than entrectinib, with IC$_{50}$ values of > 10 μM for all CYPs tested except for CYP2C8 (IC$_{50}$ \~ 4.9 μM).

In vitro studies using human hepatocytes showed that entrectinib caused CYP3A4 mRNA induction by 48% of the positive control (rifampicin) at 10 μM and by 12.5% at 3 μM (Table S2). However, CYP3A enzyme activity was induced less than 10% of positive control using 10 μM entrectinib. M5 had no significant impact on the mRNA expression or activity of CYP3A4 (Table S3). Entrectinib did not significantly induce CYP1A2 mRNA or enzyme activity. Due to the positive CYP3A induction signal, induction of CYP2C enzymes was also investigated. Entrectinib induced CYP2C8 and CYP2C9 mRNA levels by 31% and 38%, respectively, of positive control levels at a test concentration of 3 μM, and by 90% and 109%, respectively, at a test concentration of 10 μM. M5 had no significant impact on the activities of the CYPs tested (CYPs 1A2, 2B6, 2C19, and 3A4).

---

![Figure 1](median_entrectinib_plasma_concentration_time_profiles_following_a_single_oral_dose_of_entrectinib_alone_or_with_multiple_doseitraconazole_a_upper_panels_or_rifampin_c_lower_panels.png)

**Fig. 1** Median Entrectinib Plasma Concentration–Time Profiles Following a Single Oral Dose of Entrectinib Alone or With Multiple Dose Itraconazole (a, b, Upper Panels) or Rifampin (c, d, Lower Panels)
**In vitro p-gp interactions with entrectinib and m5**

Entrectinib showed a high efflux ratio in the in vitro P-gp assay, but did not display sensitivity to a P-gp inhibitor. In addition, entrectinib penetrated the brain in several in vivo models at steady-state, indicating a much lower P-gp effect at the level of the blood–brain barrier as suggested by the in vitro efflux ratio. Taken together, these data suggest entrectinib is a poor P-gp substrate. These data have recently been described by Fischer et al. [9] and will not be discussed further in the current manuscript. Entrectinib inhibits P-gp with an IC$_{50}$ of 1.33 μM. M5 is both a substrate for and inhibitor of P-gp with an IC$_{50}$ value of 10.1 μM.

**Subject disposition and demographics**

In Study 1, a total of 20 subjects (10 per cohort) were enrolled and received treatment and 19 subjects completed the study. One subject in Cohort 1 withdrew during Period 2 prior to receiving entrectinib. Demographic characteristics were similar across both cohorts; all subjects were male, and the majority (75%) were White. Median age was 45 years (range 28 to 55 years) in Cohort 1, and 27.5 years (range 18 to 48 years) in Cohort 2.

In Study 2, a total of 15 subjects were enrolled, and 14 subjects received midazolam on Day 1 (ie, 1 subject was withdrawn by the investigator prior to treatment). Two subjects withdrew prior to receiving entrectinib; one subject withdrew due to progressive disease and 1 subject withdrew due to an adverse event. On Day 8, the remaining 12 subjects received midazolam 1 h after entrectinib. Of the 14 subjects who received treatment, the majority were female (64%), and White (93%) and the median age was 64.5 years (range 50 to 79 years).

In Study 3, 10 subjects were enrolled, received treatment, and completed the study. All subjects were male and the majority (80%) were White. Median age was 29.5 years (range 24 to 53 years).

**Pharmacokinetic results**

**Effect of a strong cyp3a4 inhibitor (Itraconazole) and strong cyp3a4 inducer (Rifampin) on the pharmacokinetics of single dose entrectinib (study 1)**

Median plasma concentration–time profiles for entrectinib in the presence and absence of itraconazole and rifampin are presented in Fig. 1. In Cohort 1, statistical analysis suggested that entrectinib C$_{\text{max}}$ and AUC$_{\text{inf}}$ were approximately 73%, and 504% higher, respectively when entrectinib was coadministered with itraconazole compared with entrectinib alone. Entrectinib median T$_{\text{max}}$ occurred approximately 3 h later when entrectinib was administered with itraconazole compared with entrectinib alone (Table 3). The geometric mean t$_{1/2}$ of entrectinib was notably longer when entrectinib was administered with itraconazole (50 h) compared with

| Analyte | PK Parameter | Entrectinib 100 mg Alone (N = 10) | Entrectinib 100 mg with Itraconazole (N = 10) | Ratio of adjusted Geometric Means (90% CI) | Entrectinib 600 mg Alone (N = 10) | Entrectinib 600 mg with Rifampin (N = 10) | Ratio of Adjusted Geometric Means (90% CI) |
|---------|--------------|----------------------------------|-----------------------------------------------|-------------------------------------------|----------------------------------|------------------------------------------|-------------------------------------------|
| Entrectinib | AUC$_{\text{inf}}$ (nM•h) | 6190 (50%) | 36,100 (17%) | 6.04 (4.54, 8.04) | 36,300 (28%) | 8440 (29%) | 0.23 (0.18, 0.30) |
|          | C$_{\text{max}}$ (nM) | 358 (35%) | 615 (17%) | 1.73 (1.37, 2.18) | 1810 (25%) | 807 (26%) | 0.44 (0.35, 0.56) |
|          | T$_{\text{max}}$ (h) | 2.0 (1.0, 3.0) | 5.0 (2.0, 8.0) | ND | 3.5 (2.0, 5.0) | 2.0 (2.0, 5.0) | ND |
|          | t$_{1/2}$ (h) | 20.2 (17%) | 49.8 (22%) | ND | 16.7 (16%) | 9.9 (26%) | ND |
| M5      | AUC$_{\text{inf}}$ (nM•h) | 1710 (30%) | 4310 (30%) | ND | 11,000 (44%) | 1530 (28%) | ND |
|          | C$_{\text{max}}$ (nM) | 52.3 (37%) | 31.5 (42%) | ND | 383 (56%) | 108 (23%) | ND |
|          | T$_{\text{max}}$ (h) | 5.0 (3.0, 5.0) | 6.0 (5.0, 48.0) | ND | 5.0 (4.0, 5.0) | 3.0 (2.0, 6.0) | ND |
|          | t$_{1/2}$ (h) | 40.8 (22%) | 88.0 (32%) | ND | 33.8 (12%) | 31.1 (28%) | ND |
| M5/Entrectinib ratio | AUC$_{\text{inf}}$ | 0.288 (28%) | 0.124 (29%) | ND | 0.337 (56%) | 0.187 (28%) | ND |
|          | C$_{\text{max}}$ | 0.151 (26%) | 0.0538 (34%) | ND | 0.234 (59%) | 0.136 (23%) | ND |

*Unadjusted geometric means (geometric coefficients of variation) for all except T$_{\text{max}}$ which is median (minimum, maximum), and M5/entrectinib ratios which are arithmetic mean (coefficients of variation)*

'Unadjusted’ refers to raw data, and ‘adjusted’ refers to data that have been subjected to statistical analysis. Statistical comparisons were only conducted for entrectinib AUC$_{\text{inf}}$ and C$_{\text{max}}$.
entrectinib alone (20 h). Entrectinib was partially converted to M5 with a median $T_{\text{max}}$ of 5 and 6 h when entrectinib was administered alone and with itraconazole, respectively. Mean M5 $t_{1/2}$ was notably longer when entrectinib was administered with itraconazole (88 h) compared with entrectinib alone (41 h). The mean M5/entrectinib ratios for AUC$_{\text{inf}}$ showed that M5 exposure was approximately 29% of entrectinib exposure when entrectinib was administered alone, compared with 12% when it was coadministered with itraconazole.

In Cohort 2, statistical analysis suggested that entrectinib $C_{\text{max}}$ and AUC$_{\text{inf}}$ were approximately 56%, and 77% lower, respectively when entrectinib was coadministered with rifampin compared with entrectinib alone. Entrectinib median $T_{\text{max}}$ occurred approximately 1.5 h earlier following administration of entrectinib with rifampin compared with entrectinib alone (Table 3). Entrectinib mean $t_{1/2}$ was shorter (10 h) when administered with rifampin compared with entrectinib alone (17 h). The median $T_{\text{max}}$ for M5 was 5 and 3 h for entrectinib alone and with rifampin, respectively. The mean $t_{1/2}$ was estimated to be approximately 31 to 34 h following administration of entrectinib alone and with rifampin. The mean M5/entrectinib ratios for AUC$_{\text{inf}}$ showed that M5 exposure was approximately 34% of entrectinib exposure when entrectinib was administered alone, compared with 19% of entrectinib exposure when coadministered with rifampin.

**Effect of Entrectinib on the pharmacokinetics of cyp3a4 substrates (Midazolam and 1'-hydroxymidazolam; study 2)**

Median plasma concentration–time profiles for midazolam in the presence and absence of entrectinib are presented in Fig. 2, and a summary of the PK parameters for midazolam

---

**Fig. 2**  Median Midazolam Plasma Concentration–Time Profiles Following a Single Oral Dose of Midazolam Alone or With Single (a, b, Upper Panels) or Multiple (c, d, Lower Panels) Dose Entrectinib
and 1’-hydroxymidazolam are presented in Table 4. A single oral dose of entrectinib did not appear to affect the total exposure (AUC\text{inf}) of midazolam, with point estimates for the geometric mean ratios close to 1 and 90% CIs within 0.80 to 1.25. Peak midazolam concentrations (C\text{max}) were however reduced by approximately 35% following coadministration with single dose entrectinib. Multiple doses of entrectinib increased exposure of midazolam by approximately 50% (AUC\text{inf}), whereas C\text{max} decreased by approximately 21%. Moderate inter-subject variability was observed for both midazolam and its metabolite with coefficients of variation (CV\%) for C\text{max} and AUC parameters of up to 60%. The mean t\text{1/2} of midazolam was similar when midazolam was administered with a single dose of entrectinib (5.73 h) compared to alone (6.35 h), whereas administration of multiple doses of entrectinib with midazolam increased midazolam t\text{1/2} to 8.13 h. Similar trends were observed for the AUC\text{inf} and C\text{max} of 1’-hydroxymidazolam when midazolam was administered in the presence and absence of single and multiple-dose entrectinib. The metabolic ratio of metabolite to parent for both AUC\text{inf} and C\text{max} was not affected by coadministration of single-dose entrectinib, but was decreased (point estimates of approximately 59% to 64\%) by coadministration with multiple-dose entrectinib.

### Discussion

#### Entrectinib as a victim of DDIs

Previous clinical studies with entrectinib have demonstrated that it is primarily cleared by metabolism and forms a major circulating and active metabolite (M5) that is thought to contribute to the clinical efficacy of the drug. Other, more minor pathways of metabolism included direct glucuronidation (M11) as well as N-oxidation and benzyl hydroxylation by CYP enzymes. Together these additional routes accounted for <25% metabolism in vitro and none of the products were major circulating metabolites except M11 [7]. As M11 is a glucuronide conjugate which is not expected to show pharmacological activity, further in vivo examination

| Analyte                  | PK Parameter\(^a\) | Midazolam Alone (N = 10) | Midazolam with Single Dose Entrectinib (N = 10) | Midazolam with Multiple Dose Entrectinib (N = 10) | Ratio of adjusted geometric means (90\% Confidence Intervals) |
|--------------------------|-------------------|--------------------------|-----------------------------------------------|---------------------------------------------------|-----------------------------------------------------------------|
| Midazolam AUC\text{inf} (nM•h) | 45.9 (61\%)        | 43.7 (77\%)              | 62.1 (79\%)                                   | 1.00 (0.87, 1.16)                                   | 1.50 (1.29, 1.73)                                               |
| C\text{max} (nM)         | 19.0 (64\%)        | 12.9 (64\%)              | 14.4 (50\%)                                   | 0.66 (0.56, 0.78)                                   | 0.79 (0.66, 0.94)                                               |
| T\text{max} (h)          | 0.49 (0.25, 1.00)  | 0.75 (0.48, 23.6\(^b\))  | 0.50 (0.10, 0.50)                             | ND                                                 | ND                                                              |
| t\text{1/2} (h)          | 5.2 (68\%)         | 5.33 (44\%)              | 6.4 (68\%)                                    | ND                                                 | ND                                                              |
| 1’-hydroxymidazolam AUC\text{inf} (nM•h) | 14.9 (60\%)        | 14.4 (52\%)              | 14.0 (42\%)                                   | 0.96 (0.83, 1.10)                                   | 0.89 (0.70, 1.12)                                               |
| C\text{max} (nM)         | 6.57 (76\%)        | 4.21 (48\%)              | 3.51 (47\%)                                   | 0.62 (0.50, 0.76)                                   | 0.49 (0.36, 0.67)                                               |
| T\text{max} (h)          | 0.5 (0.25, 1.00)   | 1.0 (0.48, 23.6)         | 0.75 (0.5, 5.97)                               | ND                                                 | ND                                                              |
| t\text{1/2} (h)          | 3.71 (81\%)        | 4.56 (49\%)              | 5.37 (75\%)                                   | ND                                                 | ND                                                              |

\(AUC\text{inf}\) area under the plasma concentration–time curve extrapolated to infinity, \(C\text{max}\) maximum plasma concentration, \(ND\) not done, \(t\text{1/2}\) terminal elimination half-life, \(T\text{max}\) time of maximum plasma concentration

\(^a\)Unadjusted geometric means (geometric coefficients of variation) for all except \(T\text{max}\) which is median (minimum, maximum)

\(^b\)Maximum value was due to one outlying subject

Unadjusted’ refers to raw data, and ‘adjusted’ refers to data that have been subjected to statistical analysis. Statistical comparisons were only conducted for midazolam AUC\text{inf} and C\text{max}.

Coadministration of entrectinib with digoxin had a limited effect on the pharmacokinetics of digoxin (Table 5). Digoxin absorption was slower and \(T\text{max}\) occurred approximately 1 h later when a single 600 mg dose of entrectinib was coadministered with digoxin. Digoxin peak \(C\text{max}\) and total exposure (AUC\text{inf}) after coadministration of entrectinib were 28\% and 18\% higher, respectively, than when digoxin was taken alone. The fraction of the digoxin dose excreted in urine was comparable (44\% vs. 40\%). Exploratory analysis showed that the geometric mean ratio of digoxin \(\text{CLR}\) with and without coadministration of entrectinib was 94.6\% (90\% CI: 90.9\%, 98.4\%) indicating minimal effect of entrectinib on digoxin renal clearance.

### Effect of entrectinib on the pharmacokinetics of a sensitive P-gp substrate (Digoxin; study 3)

Median plasma concentration–time profiles and cumulative urinary excretion-time profiles for digoxin in the presence and absence of entrectinib are presented in Fig. 3.

#### Effect of entrectinib on the pharmacokinetics of a sensitive P-gp substrate (Digoxin; study 3)

Median plasma concentration–time profiles and cumulative urinary excretion-time profiles for digoxin in the presence and absence of entrectinib are presented in Fig. 3.

Table 4 Summary of midazolam and 1’-hydroxymidazolam plasma pharmacokinetic parameters with and without coadministration of single and multiple dose entrectinib (600 mg/day) following a single 7.5 mg midazolam dose

| Analyte                  | PK Parameter\(^a\) | Midazolam Alone (N = 10) | Midazolam with Single Dose Entrectinib (N = 10) | Midazolam with Multiple Dose Entrectinib (N = 10) | Ratio of adjusted geometric means (90\% Confidence Intervals) |
|--------------------------|-------------------|--------------------------|-----------------------------------------------|---------------------------------------------------|-----------------------------------------------------------------|
| Midazolam AUC\text{inf} (nM•h) | 45.9 (61\%)        | 43.7 (77\%)              | 62.1 (79\%)                                   | 1.00 (0.87, 1.16)                                   | 1.50 (1.29, 1.73)                                               |
| C\text{max} (nM)         | 19.0 (64\%)        | 12.9 (64\%)              | 14.4 (50\%)                                   | 0.66 (0.56, 0.78)                                   | 0.79 (0.66, 0.94)                                               |
| T\text{max} (h)          | 0.49 (0.25, 1.00)  | 0.75 (0.48, 23.6\(^b\))  | 0.50 (0.10, 0.50)                             | ND                                                 | ND                                                              |
| t\text{1/2} (h)          | 5.2 (68\%)         | 5.33 (44\%)              | 6.4 (68\%)                                    | ND                                                 | ND                                                              |
| 1’-hydroxymidazolam AUC\text{inf} (nM•h) | 14.9 (60\%)        | 14.4 (52\%)              | 14.0 (42\%)                                   | 0.96 (0.83, 1.10)                                   | 0.89 (0.70, 1.12)                                               |
| C\text{max} (nM)         | 6.57 (76\%)        | 4.21 (48\%)              | 3.51 (47\%)                                   | 0.62 (0.50, 0.76)                                   | 0.49 (0.36, 0.67)                                               |
| T\text{max} (h)          | 0.5 (0.25, 1.00)   | 1.0 (0.48, 23.6)         | 0.75 (0.5, 5.97)                               | ND                                                 | ND                                                              |
| t\text{1/2} (h)          | 3.71 (81\%)        | 4.56 (49\%)              | 5.37 (75\%)                                   | ND                                                 | ND                                                              |
of this metabolite was not required. The in vitro studies in human biomaterials described here showed that while several CYPs were able to metabolise entrectinib, the most important enzyme was CYP3A4. This enzyme was also shown to be involved in both the formation and the further metabolism of M5. To assess the relevance of these findings, a clinical study was conducted to investigate the magnitude of any changes in entrectinib exposure when entrectinib is coadministered with modulators of CYP3A4.

Coadministration of the strong CYP3A4 inhibitor itraconazole with entrectinib had a significant effect on entrectinib exposure with an increase in AUC$_{\text{inf}}$ of approximately sixfold. M5 exposures also increased although to a lesser extent than the parent (AUC$_{\text{inf}}$ increased by approximately 2.5-fold), with metabolite/parent ratios falling from approximately 29% to 12% in the presence of itraconazole. Coadministration of the strong CYP3A4 inducer rifampin with entrectinib also had a significant effect of entrectinib
exposures with a decrease in $\text{AUC}_{\text{inf}}$ of approximately 77%. M5 exposures also decreased although again to a lesser extent than the parent. The changes in M5 exposure when entrectinib was coadministered with itraconazole and rifampin confirm the in vitro finding that M5 is further metabolized by CYP3A4, and hence both its formation and clearance may be affected by modulators of CYP3A4 activity. Overall, these data show that entrectinib is a sensitive substrate of CYP3A4 with a fraction metabolized ($f_m$) of 0.78 for entrectinib clearance estimated using physiologically-based pharmacokinetic (PBPK) modelling approaches (manuscript in preparation). Subsequent PBPK analysis has suggested that the dose of entrectinib should be reduced when coadministered with strong or moderate CYP3A4 inhibitors from 600 to 100 mg or 200 mg, respectively. Given the magnitude of reduction in entrectinib exposure when coadministered with rifampin, coadministration of entrectinib with strong CYP3A inducers is not recommended.

Itraconazole is also known to inhibit P-gp and in vitro studies suggested that entrectinib is a P-gp substrate, albeit a poor one. The limited effect of itraconazole on the peak concentrations of entrectinib after a single dose did not suggest that P-gp inhibition has a marked effect on entrectinib absorption. These data are consistent with the moderate to high entrectinib bioavailability implying that efflux transporters in gastrointestinal enterocytes do not significantly limit systemic drug availability.

**Entrectinib as a perpetrator of DDIs**

The potential of entrectinib and M5 to inhibit or induce CYPs was also investigated in vitro. The studies in human liver microsomes suggested that entrectinib has the potential to inhibit CYP3A4/5 with an $IC_{50}$ of 2 μM. The $IC_{50}$ values for entrectinib with the other CYPs tested were >10 μM, suggesting the potential for clinically relevant DDIs with these CYPs is low, and hence no formal clinical studies to assess possible interactions with substrates of these CYPs has been conducted. M5 had $IC_{50}$ values >10 μM for several CYPs except for CYP2C8 where the $IC_{50}$ was approximately 4.9 μM. The estimated free $C_{\text{max}}$ of M5 in plasma from patients treated at 600 mg QD is 0.0134 μM, which is >300-fold lower than the $IC_{50}$ and hence the potential for entrectinib to cause DDIs with CYP2C8 substrates via M5 is considered to be low. Note, the actual unbound fraction of M5 is <1% in human plasma (Roche data on file), but a value of 1% has been used for initial risk assessment based on FDA guidance [10].

Given the potential for entrectinib to inhibit and/or induce CYP3A4, a clinical study was conducted to determine the effect of entrectinib on midazolam, which is a sensitive index CYP3A4 substrate recommended for such assessments [11]. Baseline (Day 1) midazolam and 1’- hydroxymidazolam plasma concentrations and PK parameters were generally consistent with literature reports [12, 13]. Coadministration of midazolam with a single dose of entrectinib did not have a significant effect on midazolam total exposure ($\text{AUC}_{\text{inf}}$) although peak plasma concentrations were reduced by approximately 35%. It should be noted that the observed change in $C_{\text{max}}$ is not anticipated to be due to enzyme induction, but rather may be due to decreased rate or extent of midazolam absorption when administered in combination with entrectinib. For example, midazolam exposure has previously been shown to be susceptible to food and changes in gastric pH [14, 15], and therefore its absorption may be affected by the acidifying agent included in the entrectinib formulation.

Table 5 Summary of digoxin plasma pharmacokinetic parameters with and without coadministration of a single 600 mg dose of entrectinib following a single 75 mg digoxin dose

| Analyte          | PK parametera | Digoxin Alone (N = 10) | Digoxin with Entrectinib (N = 10) | Ratio of adjusted geometric means (90% Confidence Intervals) |
|------------------|---------------|------------------------|----------------------------------|-------------------------------------------------------------|
|                  | $\text{AUC}_{\text{inf}}$ (nM•h) | 34.2 (14%)             | 40.4 (17%)                       | 1.18 (1.06, 1.32)                                           |
|                  | $C_{\text{max}}$ (nM)           | 1.97 (29%)             | 2.52 (39%)                       | 1.28 (0.98, 1.67)                                           |
|                  | $T_{\text{max}}$ (h)            | 1.0 (0.5, 1.0)         | 2.0 (0.5, 3.0)                   | ND                                                          |
|                  | $t_{1/2}$ (h)                  | 35.9 (15%)             | 38.4 (37%)                       | ND                                                          |
|                  | $\text{CLR}$ (mL/min)          | 130 (16%)              | 123 (13%)                        | 0.95 (0.91, 0.98)                                           |
|                  | $f_e$ (%)                     | 40.2 (13%)             | 44.0 (14%)                       | ND                                                          |

$AUC_{\text{inf}}$ area under the plasma concentration–time curve extrapolated to infinity. $\text{CLR}$ renal clearance, $C_{\text{max}}$ maximum plasma concentration, $f_e$ (%) percent of dose excreted unchanged in urine, ND not done, $t_{1/2}$ terminal elimination half-life, $T_{\text{max}}$ time of maximum plasma concentration

*aUnadjusted geometric means (geometric coefficients of variation) for all except $T_{\text{max}}$ which is median (minimum, maximum)

‘Unadjusted’ refers to raw data, and ‘adjusted’ refers to data that have been subjected to statistical analysis. Statistical comparisons were only conducted for digoxin $AUC_{\text{inf}}$, $C_{\text{max}}$ and $\text{CLR}$.
CYP3A4 inducers. Entrectinib is also a weak inhibitor of CYP3A4 although no clinically significant interaction with a sensitive CYP3A4 substrate was observed. Entrectinib does not induce CYP3A4 in vivo at the recommended dose and therefore clinically relevant interactions with CYP3A4 (or CYP2C) substrates are not expected. No clinically relevant interaction was observed with a P-gp substrate and therefore entrectinib can be coadministered with P-gp substrates without dose adjustment.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s10637-021-01156-9.

Acknowledgements The authors would like to thank Samantha Abel, PhD, Valley Writing Solutions Ltd (Canterbury, UK) for medical writing assistance with the preparation of this manuscript.

Author contributions All authors were involved in revising the manuscript critically for important intellectual content, approved the final version, and agree to be accountable for the work. Additionally the authors contributed as follows: Georgina Meneses-Lorente: Acquisition, analysis and interpretation of data; drafting of the manuscript. Stephen Fowler: Study concept and design; analysis and interpretation of data; drafting of the manuscript. Elena Guerini: Analysis and interpretation of data. Karey Kowalski: Study concept and design; acquisition, analysis and interpretation of data. Edna Chow-Maneval: Study concept and design; acquisition of data. Li Yu: Analysis and interpretation of data. Francois Mercier: Interpretation of data; drafting of the manuscript. Mohammed Ullah: Study concept and design, acquisition, analysis and interpretation of data; drafting of the manuscript. Kenichi Umehara: Analysis and interpretation of data. Andreas Brink: Interpretation of data. Vincent Buchheit: Analysis of data. Elke Zwanziger: Acquisition and analysis of data. Alex Phipps: Study design. Nassim Djebli: Analysis and interpretation of data.

Funding These studies were funded by F. Hoffmann-La Roche Ltd (formerly Ignity Inc., a member of the Roche Group). The in vitro work was also funded by F. Hoffmann-La Roche Ltd.

Data availability Qualified researchers may request access to individual patient level data through the clinical study data request platform (https://vivli.org/). Further details on Roche’s criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche’s Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

Declarations

Ethics approval All studies were approved by the relevant ethics committees, and were conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice guidelines.

Research involving human participants and/or animals Registration number (Study 2): NCT03330990 (first posted online November 6, 2017). As studies 1 and 3 are phase 1 trials in healthy subjects, they are not required to be registered.

Informed consent In all 3 studies, subjects provided written informed consent.
Consent to participate  Informed consent was obtained from all individual participants included in the study.

Conflicts of interest  G.M.-L. is an employee of Roche Products Ltd. E.G. and A.P. are employees and stockholders of F. Hoffmann-La Roche Ltd, N.D. is an employee of Ignyta (owned by F. Hoffmann-La Roche Ltd), E. C-M. and K.K. were employees of Ignyta (owned by F. Hoffmann-La Roche Ltd) during the time this work was conducted. F.M., V.B., A.B., S.F., E.Z. and K.U. are employees of Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland, M. U. was an employee of Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland during the time this work was conducted. L.Y. is a former employee of the Roche Innovation Center, Little Falls, NJ, USA.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Weinstein IB, Joe A (2008) Oncogene addiction. Cancer Res 68 (9):3077–3080; discussion 3080. https://doi.org/10.1158/0008-5472.CAN-07-3293
2. Weinstein IB, Joe AK (2006) Mechanisms of disease: Oncogene addiction—a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 3(8):448–457. https://doi.org/10.1038/ncponc0558
3. Shaw AT, Engeljman JA (2013) ALK in lung cancer: past, present, and future. J Clin Oncol 31(8):1105–1111. https://doi.org/10.1200/JCO.2012.44.5353
4. Patel MR, Bauer TM, Liu SV, Drilon AE, Wheler JJ, Shaw AT, Farago AF, Ou S-HL, Luo D, Yeh L, Hornby Z, Senderowicz AM, Lim J (2015) STARTKR-1: Phase 1/2a study of entrectinib, an oral Pan-Trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations. Journal of Clinical Oncology 33 (15_suppl):2596–2596. https://doi.org/10.1200/jco.2015.33.15_suppl.2596
5. Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, Lee J, Bauer TM, Farago AF, Wheler JJ, Liu SV, Doebelé R, Giannetta L, Cerea G, Marra pesa G, Shirru M, Amato A, Bencardino K, Palmeri L, Sartore-Bianchi A, Vanzulli A, Cresta S, Damian S, Duca M, Ardini E, Li G, Christiansen J, Kowalski K, Johnson AD, Patel R, Luo D, Chow-Maneval E, Hornby Z, Multani PS, Shaw AT, De Braud FG (2017) Safety and Antitumor Activity of the Multigated Pan-Trk, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTKR-1). Cancer Discov 7(4):400–409. https://doi.org/10.1158/2159-8290.CD-16-1237
6. Doebelé RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BS, Tosi D, Besse B, Chawla SP, Bazarhovena L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL Jr, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD (2020) Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol 21(2):271–282. https://doi.org/10.1016/S1470-2045(19)30691-6
7. Meneses-Lorente G, Bentley D, Guerini E, Kowalski K, Chow-Maneval E, Yu L, Brink A, Djebli N, Mercier F, Buchheit V, Phipps A (2021) Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors. Invest New Drugs. https://doi.org/10.1007/s10637-020-01047-5
8. US Food and Drug Administration Center for Drug Evaluation and Research (2020) Guidance for Industry: Safety Testing of Drug Metabolites
9. Fischer H, Ullah M, de la Cruz CC, Hunsaker T, Senn C, Wirz T, Wagner B, Dragano D, Vazvaei F, Donzelli M, Puehler A, Merchant M, Yu L (2020) Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein. Neuro Oncol 22(6):819–829. https://doi.org/10.1093/neuonc/noaa052
10. US Food and Drug Administration Center for Drug Evaluation and Research (2020) Guidance for Industry. In Vitro Drug Interaction Studies — Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions
11. US Food and Drug Administration Center for Drug Evaluation and Research Drug Development and Drug Interactions. https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions. Accessed 12 February 2021
12. Zhan M, Talaty J, Sandhu P, McCrea J, Patnaik A, Tolcher A, Palcza J, Orford K, Breidinger S, Narasimhan N, Pariendiano B, Lush R, Papadopoulos KP, Wagner JA, Trucksis M, Agrawal N (2014) Lack of meaningful effect of ridaforolimus on the pharmacokinetics of midazolam in cancer patients: model prediction and clinical confirmation. J Clin Pharmacol 54(11):1256–1262. https://doi.org/10.1002/jcph.331
13. Wang Z, Yang J, Kirk C, Fang Y, Alsina M, Badros A, Papadopoulos K, Wong A, Woo T, Bomba D, Li J, Infante JR (2013) Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib. Drug Metab Dispos 41(1):230–237. https://doi.org/10.1124/dmd.112.1047662
14. Bornemann LD, Crews T, Chen SS, Twardak S, Patel IH (1986) Influence of food on midazolam absorption. J Clin Pharmacol 26(1):55–59. https://doi.org/10.1002/jcph.492260103.x
15. Zhang J, Niu S, Zhang H, Streisand JB (2002) Oral mucosal absorption of midazolam in dogs is strongly pH dependent. J Pharm Sci 91(4):980–982. https://doi.org/10.1016/j.jsps.2001.10.0079
16. Parrott N, Stillhart C, Lindenberg M, Wagner B, Kowalski K, Guerini E, Djebli N, Meneses-Lorente G (2020) Physiologically Based Absorption Modelling to Explore the Impact of Food and Gastric pH Changes on the Pharmacokinetics of Entrectinib. AAPS J 22(4):78. https://doi.org/10.1208/s12248-020-00463-y
17. US Food and Drug Administration Center for Drug Evaluation and Research (2020) Guidance for Industry. Clinical Drug Interaction Studies - Cytochrome 450 Enzyme- and Transporter-Mediated Drug Interactions.
18. Lutz JD, Kirby BJ, Wang L, Song Q, Ling J, Massetto B, Worth A, Kearney BP, Mathias A (2018) Cytochrome P450 3A Induction Predicts P-glycoprotein Induction; Part 1: Establishing Induction Relationships Using Ascending Dose Rifampin. Clin Pharmacol Ther 104(6):1182–1190. https://doi.org/10.1002/cpt.1073
19. Lutz JD, Kirby BJ, Wang L, Song Q, Ling J, Massetto B, Worth A, Kearney BP, Mathias A (2018) Cytochrome P450 3A Induction Predicts P-glycoprotein Induction; Part 2: Prediction of Decreased Substrate Exposure After Rifabutin or Carbamazepine. Clin Pharmacol Ther 104(6):1191–1198. https://doi.org/10.1002/cpt.1072
20. Rozlytrek Prescribing Information (2019) https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf. Accessed 12 February 2021

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.